Related Experiment Videos
Solubility changes on mixing short- and long-acting insulin preparations
Summary
Mixing short-acting insulins with intermediate-acting ones can cause significant solubility loss, particularly with certain porcine insulin mixtures over time. This finding is crucial for understanding potential clinical relevance in insulin therapy transitions.
Area of Science:
- Pharmaceutical Sciences
- Endocrinology
- Analytical Chemistry
Background:
- Insulin therapy often involves mixing different insulin types for patient convenience.
- The stability and solubility of insulin mixtures are critical for predictable glycemic control.
- Previous research has not fully elucidated the solubility dynamics of short-acting insulins when combined with intermediate-acting formulations.
Purpose of the Study:
- To investigate the in vitro solubility of short-acting insulins when mixed with intermediate-acting insulins.
- To quantify the extent of solubility loss and its dependence on mixing time and insulin type/manufacturer.
Main Methods:
- High-performance liquid chromatography (HPLC) was employed to determine insulin solubility.
- Porcine and human insulin preparations from three manufacturers were tested.
- Mixtures were analyzed at various time points ranging from 0 to 24 hours.
Main Results:
- Mixtures of human insulins showed minimal solubility loss.
- Mixtures of porcine Velosulin and Insulatard exhibited small solubility reductions.
- A specific mixture of porcine Actrapid MC and Monotard MC demonstrated a 60-95% loss of soluble insulin, increasing with mixing duration.
Conclusions:
- Short-acting insulins can lose solubility when mixed with certain long- or intermediate-acting insulin formulations in vitro.
- The observed solubility loss is formulation-dependent and time-sensitive.
- These findings suggest potential clinical implications for patients transitioning between different insulin mixtures.